Page 30 - Amgen News Today

Amgen Inc. (NASDAQ:AMGN – Free Report) – Stock analysts at Zacks Research reduced their Q2 2024 EPS estimates for Amgen in a research report issued on Thursday, May 23rd. Zacks Research analyst S. Ganoria now anticipates that the medical research company will post earnings of $4.85 per share for the quarter, down from their prior […]

Amgen Inc. (NASDAQ:AMGN – Free Report) – Investment analysts at Zacks Research decreased their Q2 2024 earnings per share estimates for Amgen in a report issued on Thursday, May 23rd. Zacks Research analyst S. Ganoria now forecasts that the medical research company will earn $4.85 per share for the quarter, down from their previous estimate […]

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twenty-one analysts that are presently covering the firm, Marketbeat reports. Ten research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month target price […]

Over 80 experimental obesity drugs have reached the human testing stage

Scientists are finding that anti-obesity medicines can also help many other diseases

SAN DIEGO — After 1 year of biologic therapy, patients with COPD and Th2 inflammation experienced fewer exacerbations and hospitalizations, according to research presented at the American Thoracic Society International Conference.“Because we took a real-world approach including all comers with COPD who received biologics, this may be more directly relatable to patients at large and

The Amgen of 2027 could be much be larger than some investors expect.

Health news and commentary gathered by <em>MedPage Today</em> staff

Eculizumab-aeeb (Bkemv; Amgen) is approved for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Treatment-Related Early Increase in Serum TTR is Associated With Lower Cardiovascular Mortality in ATTR-CM: Insights From ATTRibute-CM Amrut...